The 2nd season of RSV universal prophylaxis against RSV in infants with #nirsevimab in Galicia has started, and with that the 1st weekly report of #NIRSEGAL study. These reports will be available at nirsegal.es/en. See first full report at nirsegal.es/informe-en/lat…👇 1/x

You can follow the weekly update and new data at nirsegal.es/en Eric Topol Louis Bont ReSViNET AEP Xunta de Galicia Consellería de Sanidade Pepe Serrano #Vacúnate 🙏 Antonio Iofrío Irene Maté💙 Comité Vacunas e Inmunizaciones-AEP Maria Garcés-Sánchez ESPIDSociety Peter Openshaw GENVIP Academia VRS - RSV Academy 7/7

El protocolo NIRSEGAL, tal como se aplica y esta previsto, está publicado en: tandfonline.com/doi/full/10.10… 3/x

El análisis de los primeros resultados de mitad de temporada fue publicado en The Lancet Infectious Diseases : thelancet.com/journals/lanin… y el resultado de toda la temporada se presentará pronto en reuniones internacionales y publicaciones 4/x

La temporada de VRS 2024-2025 aún no ha comenzado. 5/x

Aquí ya puedes ver los resultados completos de 2023-2024, con diferencias en las tasas de hospitalización acumuladas entre los que recibieron nirsevimab y aquellos en su segunda temporada. 6/x

La aceptación de la inmunización ha sido excelente hasta ahora, como en la temporada anterior. 7/x

Eric Topol Louis Bont ReSViNET AEP Xunta de Galicia Consellería de Sanidade Pepe Serrano #Vacúnate 🙏 Antonio Iofrío Irene Maté💙 Comité Vacunas e Inmunizaciones-AEP Maria Garcés-Sánchez ESPIDSociety Peter Openshaw GENVIP Academia VRS - RSV Academy Vacunas.org WHO at the EU Simon Drysdale SEPEAP Medscape Pediatrics CHUS PEDIATRIA SOPEBA Urgencias de Pediatría - Hospital de Cruces Xavier Sáez Llorens 9/9

New NIRSEGAL weekly report available (week 43,2024). Check it out at nirsegal.es/en New features added, including acute bronchiolitis in primary care

In this week NIRSEGAL report (nirsegal.es/en) we also added a new feature: primary care assistance for acute bronchiolitis.Check the outstanding reduction that the immunization program with nirsevimab provided last season compared to the pre-nirsevimab era! #NIRSEGAL

Today we launch an eye-opening video that sheds light on the serious consequences of Respiratory Syncytial Virus (RSV) infections, especially for infants and young children.

🚨 Breaking: Full 2023-24 results from the NIRSE-GAL study in Galicia, Spain, confirm effectiveness of universal nirsevimab prophylaxis in preventing RSV-related hospitalizations in infants. 📖 Published today in thelancet.com/journals/lanin… The Lancet Infectious Diseases 👇1/x

The study covered 14,476 eligible infants, achieving >90% nirsevimab uptake in both seasonal and catch-up cohorts. 🌍 This is the first full season real-world evidence from a population-based longitudinal study #nirsegal study nirsegal.es/en 2/x

Key findings: Nirsevimab reduced RSV-related hospitalizations for lower respiratory tract infections (LRTIs) by 70.7% (42.4–85.1). For LRTIs requiring oxygen, effectiveness was 80.3% (54.6–91.5). #RSV #nirsevimab 3/x

💡 Sensitivity analysis showed even higher effectiveness: 81.6% for RSV-related LRTIs and 86.5% for LRTIs requiring oxygen. Nirsevimab reduced hospitalizations for all-cause bronchiolitis or bronchitis by 46% (6.8–68.7). 4/x

Nirsevimab had a dramatic impact compared to historical RSV seasons: hospitalizations dropped by 89.2% in the overall cohort and 95.2% in the seasonal cohort. 🌟 5/x

📉 For every 30 infants immunized, 1 RSV-related LRTI hospitalization was avoided. This highlights the cost-effectiveness and public health value of universal RSV prophylaxis in infants 6/x

Importantly, no severe adverse events related to nirsevimab were reported. Safety + effectiveness = game-changer for RSV prevention. 💪 #SafeAndEffective 7/7

📑 La revista The Lancet Infectious Diseases confirma el éxito de la estrategia de profilaxis universal en bebés frente al #VRS. 👉 Resultados aportados por el estudio NIRSE-GAL, liderado por el pediatra e investigador Federico Martinón-Torres. dozz.es/mcker3

Federico Martinón-Torres 🗣️ We have powerful tools to combat #RSV— the real challenge is ensuring these reach the places where the burden is greatest.🎧 Tune into #ESWIAirborne for more on RSV vaccine development with Peter Openshaw Clare Taylor shorturl.at/qnvHk #ESWIEducationHub